Fertility Clinics and Fertility Treatment in California

California is one of the largest, most diverse, and most advanced fertility-care markets in the United States. From Los Angeles, Orange County, and San Diego in Southern California to the San Francisco Bay Area, Sacramento, and communities throughout the Central Valley, patients have access to a broad range of reproductive medicine services.

California is also distinctive because fertility treatment does not operate within a single regulatory system. A fertility center may simultaneously be affected by California medical licensing laws, state tissue-bank regulations, federal requirements governing reproductive tissue, federal assisted reproductive technology reporting requirements, health insurance laws, patient privacy requirements, and California family law governing donor conception and gestational surrogacy.

For patients, therefore, understanding fertility treatment in California involves more than simply understanding IVF.

It involves understanding the entire fertility-care ecosystem.

What Is a Fertility Clinic?

A fertility clinic is generally a medical practice specializing in the diagnosis and treatment of infertility, reproductive disorders, and family-building needs.

Many fertility clinics are led by physicians specializing in reproductive endocrinology and infertility, often referred to as REI physicians. Other professionals may include embryologists, nurses, ultrasound specialists, genetic counselors, laboratory professionals, mental-health professionals, financial counselors, and specialists in male reproductive health.

Some fertility practices provide nearly every part of treatment under one organizational structure. Others coordinate with outside laboratories, surgery centers, sperm banks, egg banks, genetic testing laboratories, attorneys, pharmacies, and gestational-surrogacy professionals.

Because fertility treatment can involve medicine, genetics, laboratory science, cryogenic storage, family law, insurance, and third-party reproduction, fertility care is one of the most multidisciplinary areas of modern medicine.

Types of Fertility Clinics in California

The California fertility market includes several different clinical models. Patients should understand these differences because the organization of a fertility clinic may affect the patient experience, laboratory structure, access to physicians, treatment scheduling, and available services.

1. Academic and University-Affiliated Fertility Programs

Academic fertility programs are associated with medical schools, teaching hospitals, or major healthcare systems.

These programs may be particularly valuable for patients with complicated medical situations requiring cooperation between reproductive medicine and other specialties.

For example, a patient preparing for cancer treatment may require coordination between oncology and fertility-preservation specialists. Other patients may require maternal-fetal medicine, urology, endocrinology, genetics, gynecology, or other specialized services.

Academic programs may also participate in reproductive-medicine research and physician training.

2. Independent Private Fertility Practices

California has a substantial private fertility-medicine sector.

Independent practices can range from a single fertility specialist to sophisticated organizations with multiple physicians, laboratories, procedure facilities, and satellite offices.

The degree of integration varies considerably. Some practices perform monitoring, egg retrieval, fertilization, embryo culture, embryo transfer, and cryopreservation within the same organization. Others use affiliated or external facilities for parts of the treatment process.

3. Large Multi-Location Fertility Networks

A growing part of fertility medicine involves larger organizations operating multiple offices.

Under this model, patients may undergo consultations, blood tests, ultrasound monitoring, and routine appointments at a local office while egg retrievals, embryology procedures, and other advanced services are concentrated at a central laboratory or treatment facility.

This model can expand geographic access to fertility treatment, particularly in a state as large as California.

At the same time, patients should understand which organization is actually providing each component of their care.

4. Boutique and Concierge Fertility Practices

Boutique fertility practices generally emphasize lower patient volumes, personalized treatment plans, physician accessibility, and a more individualized patient experience.

Some patients value being treated primarily by the same physician throughout their fertility journey rather than seeing different members of a larger clinical team.

The boutique model does not necessarily mean that every service is performed within the practice. Some smaller practices work with outside embryology laboratories, surgical facilities, genetic laboratories, or reproductive tissue banks.

5. Advanced IVF and ART Centers

Some fertility centers focus heavily on assisted reproductive technology, particularly IVF.

Their operations may include highly developed embryology laboratories, cryopreservation programs, blastocyst culture, intracytoplasmic sperm injection, embryo biopsy coordination, frozen embryo transfer, and donor-assisted reproduction.

Laboratory quality is particularly important in these centers because a significant portion of IVF treatment occurs outside the patient’s body in a carefully controlled laboratory environment.

6. Fertility Preservation Programs

Another important segment of the California market focuses on fertility preservation. 

Patients may preserve fertility for either medical or personal reasons.

Medical fertility preservation can become especially important before chemotherapy, radiation therapy, surgery, or another treatment that may damage reproductive capacity.

Other patients elect to freeze eggs or sperm because they are not yet ready to have children but would like to preserve reproductive options for the future.

California law contains specific protections concerning fertility preservation when a covered medical treatment may cause iatrogenic infertility, meaning infertility caused directly or indirectly by medical treatment.

7. Third-Party Reproduction Programs

California also has a substantial third-party reproduction sector.

Third-party reproduction may involve:

• donor sperm;
• donor eggs;
• donor embryos;
• gestational carriers;
• or combinations of these services.

These cases can involve considerably more than medical treatment. Donor screening, tissue regulations, contracts, parentage, insurance, psychological considerations, genetic information, and legal representation can all become relevant.

California has particularly detailed statutory provisions governing gestational-surrogacy arrangements and donor-related issues.

Fertility Evaluation and Diagnostic Services

Fertility treatment normally begins with an evaluation rather than IVF.

A fertility specialist may examine both reproductive partners where applicable because infertility can result from female factors, male factors, combined factors, or conditions that remain unexplained after testing.

Evaluation can include a review of reproductive and medical history, menstrual history, previous pregnancies, miscarriages, medications, surgery, lifestyle factors, and family history.

Testing may include:

• ovarian reserve testing;
• hormone testing;
• anti-Müllerian hormone, or AMH, testing;
• thyroid and other endocrine testing;
• pelvic ultrasound;
• antral follicle count;
• evaluation of the uterus;
• examination of the fallopian tubes;
• semen analysis;
• sperm-function testing when clinically indicated;
• genetic screening;
• infectious-disease screening;
• and other specialized evaluations.

The purpose is not simply to determine whether infertility exists. A thorough fertility evaluation seeks to identify why conception may be difficult and which level of treatment is medically appropriate.

Ovulation Induction and Fertility Medications

Some patients do not initially require advanced assisted reproductive technology.

Ovulation induction may be used when a patient is not ovulating regularly or when physicians want to improve the probability of ovulation during a treatment cycle.

Treatment can involve oral or injectable medications accompanied by ultrasound and hormone monitoring.

Because fertility medications can sometimes cause multiple follicles to develop, appropriate clinical monitoring is important.

Treatment decisions should consider the patient’s diagnosis, age, ovarian reserve, previous treatment history, and risks associated with multiple pregnancy.

Intrauterine Insemination — IUI

Intrauterine insemination, commonly called IUI, places prepared sperm directly into the uterus around the time of ovulation.

IUI may be considered in selected cases involving unexplained infertility, ovulatory disorders, certain male-factor conditions, cervical factors, or donor sperm.

It may be performed during a natural cycle or together with medications that stimulate ovulation.

Although IUI is substantially less technologically complex than IVF, it is not appropriate for every fertility condition. Patients with severe tubal disease, significant male-factor infertility, or other conditions may require more advanced treatment.

In Vitro Fertilization — IVF

In vitro fertilization is one of the central technologies of modern reproductive medicine.

During IVF, the ovaries are generally stimulated to produce multiple follicles. The developing follicles are monitored using ultrasound and laboratory testing.

When the eggs are ready, an egg retrieval procedure is performed.

Eggs are then transferred to an embryology laboratory, where fertilization is attempted using sperm.

Successfully fertilized eggs may develop into embryos over several days. Depending upon the treatment plan, one or more embryos may subsequently be transferred to the uterus or cryopreserved for future use.

IVF is therefore not one procedure but a sequence of interconnected clinical and laboratory processes.

Intracytoplasmic Sperm Injection — ICSI

Intracytoplasmic sperm injection, or ICSI, is a laboratory procedure in which an individual sperm is injected directly into an egg.

ICSI may be used in certain cases involving male-factor infertility, previous fertilization difficulties, limited numbers of sperm, surgically retrieved sperm, or other clinical circumstances.

It is also frequently incorporated into IVF treatment plans when physicians and embryologists determine that it is appropriate.

Embryo Culture and Blastocyst Development

After fertilization, embryos may be cultured in a controlled laboratory environment.

Some embryos are cultured to the blastocyst stage, generally several days following fertilization.

The embryology laboratory monitors development and evaluates embryos according to established clinical and laboratory criteria.

Not every fertilized egg becomes a blastocyst, and not every blastocyst will result in implantation, pregnancy, or live birth.

This attrition is a fundamental part of reproductive biology and is one reason patients should understand the distinction between:

eggs retrieved → mature eggs → fertilized eggs → embryos → blastocysts → transfers → pregnancies → live births.

These are very different measures.

Preimplantation Genetic Testing

Some IVF patients consider preimplantation genetic testing.

Different types of testing serve different purposes.

PGT-A, or preimplantation genetic testing for aneuploidy, evaluates embryos for abnormalities in chromosome number.

PGT-M, or preimplantation genetic testing for monogenic conditions, may be used where there is a known risk of transmitting a specific single-gene disorder.

PGT-SR can be used in circumstances involving certain structural chromosome rearrangements.

Patients should understand both the potential benefits and limitations of genetic testing and should discuss appropriate testing with their fertility and genetics professionals.

Egg Freezing

Egg cryopreservation has become an important part of fertility medicine. A patient undergoes ovarian stimulation and egg retrieval similarly to the beginning of an IVF cycle. Mature eggs are then cryopreserved for possible future use.

Egg freezing may be undertaken because of medical treatment that threatens fertility or because a patient wishes to preserve reproductive options for personal reasons.

Age at the time eggs are frozen can materially influence their later reproductive potential. Egg freezing should therefore not be interpreted as a guarantee of a future child.

Sperm Freezing

Sperm cryopreservation may be used before medical treatment, before certain surgical procedures, for patients with declining reproductive health, as part of gender-affirming care, before anticipated absence during fertility treatment, or for other medical and family-building reasons.

Stored sperm may later be used for IUI, IVF, ICSI, or other appropriate assisted-reproduction procedures.

Embryo Cryopreservation

Embryos created through IVF can also be frozen and stored for future use. This creates important decisions beyond laboratory medicine.

Patients may need to consider:

• how long embryos will remain stored;
• who has authority to make decisions concerning them;
• what happens if partners separate;
• what happens following death or incapacity;
• future storage fees;
• whether embryos may be donated;
• and instructions concerning disposition.

Consent documentation surrounding cryopreserved embryos is therefore an important part of fertility treatment.

Male Infertility Services

Fertility medicine is not exclusively focused on female reproductive health. Male-factor infertility can involve sperm count, motility, morphology, obstruction, hormonal disorders, genetic factors, previous medical treatment, or other reproductive conditions.

Services can include semen analysis, hormonal evaluation, genetic testing, reproductive-urology consultation, sperm cryopreservation, and surgical sperm retrieval where appropriate.

Effective fertility care should evaluate male reproductive factors when relevant instead of assuming that fertility difficulty originates only with the female partner.

Treatment for Polycystic Ovary Syndrome and Ovulatory Disorders

Polycystic ovary syndrome, commonly known as PCOS, is one of the conditions frequently encountered in fertility medicine.

Treatment may involve lifestyle interventions, management of metabolic factors, ovulation-inducing medications, monitoring, IUI, or IVF depending upon the patient’s circumstances.

Other hormonal and ovulatory disorders can similarly interfere with conception.

Endometriosis and Fertility

Endometriosis can affect fertility in several ways and varies greatly in severity.  Some patients may conceive without advanced fertility treatment, while others may require reproductive surgery, fertility medications, IUI, IVF, or another individualized approach.

Treatment decisions must balance fertility goals with symptoms, age, ovarian reserve, previous surgery, and other medical considerations.

Recurrent Pregnancy Loss

Some fertility centers also evaluate patients who have experienced repeated pregnancy losses.

The evaluation may consider uterine anatomy, genetic factors, endocrine disorders, certain hematological conditions, and other possible contributing factors.

Not every miscarriage can be explained, and patients should be cautious about treatments that promise certainty where reproductive medicine itself does not support certainty.

Donor Sperm

Donor sperm is used by many different types of families, including couples experiencing male-factor infertility, single parents by choice, and LGBTQ+ families.

Donated reproductive tissue is subject to federal regulation.

The U.S. Food and Drug Administration treats donated sperm and eggs as human cells, tissues, and cellular and tissue-based products, commonly abbreviated as HCT/Ps. Establishments carrying out activities such as recovery, processing, storage, labeling, packaging, or distribution may be subject to FDA registration and other requirements under 21 CFR Part 1271.

Federal rules also establish donor-screening and infectious-disease-testing requirements, subject to specified exceptions.

Donor Eggs

Donor eggs may be used when a patient cannot reasonably use their own eggs or when donor eggs otherwise form part of a family-building plan.

Egg donation involves medical, legal, genetic, financial, and ethical considerations.

The donor typically undergoes ovarian stimulation followed by egg retrieval. The eggs may then be fertilized and embryos created for the intended parent or parents.

Some programs use fresh donations, while others use cryopreserved donor eggs.

Donor Embryos

Embryo donation can provide another family-building pathway.

Embryos originally created by other patients may, subject to appropriate consents and legal arrangements, become available for reproduction by another recipient.

Because terminology, parentage, consent, storage, and disposition can have legal significance, patients should obtain appropriate medical and legal advice.

Gestational Surrogacy in California

California has a detailed statutory framework for gestational-surrogacy arrangements.

Under California Family Code Section 7962, a gestational-carrier agreement must contain specified information, including identification of the intended parent or parents and disclosure concerning responsibility for medical expenses.

Importantly, before executing the agreement, the gestational carrier and intended parent or parents must be represented by separate independent licensed attorneys of their choosing.

The agreement must also be properly executed, and the parties may not undergo an embryo transfer or begin injectable medications in preparation for embryo transfer until the agreement has been fully executed in accordance with the statute. California law also provides mechanisms for establishing the intended parents’ parentage, including proceedings that may occur before birth.

This legal infrastructure is one reason California has become an important jurisdiction for third-party family building.

However, surrogacy arrangements are complex transactions. Medical treatment, contractual obligations, parentage, health insurance, compensation, escrow arrangements, independent legal counsel, and the rights of the gestational carrier must all be considered.

LGBTQ+ Family Building

California fertility clinics serve many LGBTQ+ individuals and couples. Depending upon the family-building plan, services may include donor sperm, donor eggs, IVF, IUI, reciprocal IVF, embryo creation, gestational surrogacy, fertility preservation, and reproductive genetic services.

California’s current insurance framework is also significant because SB 729 updated the definition and treatment of infertility coverage in a manner designed to be more inclusive of different paths to family formation.

California’s regulatory guidance makes clear that qualifying fertility coverage cannot discriminate based on characteristics including gender, gender identity, marital status, sex, or sexual orientation, while preserving appropriate physician clinical judgment.

Fertility Treatment for Single Parents

Fertility treatment is also increasingly used by people seeking to build families without a reproductive partner.

Depending upon the individual’s reproductive circumstances, treatment may involve donor sperm, donor eggs, IVF, IUI, donor embryos, or a gestational carrier.

The appropriate pathway depends upon the reproductive material available and the medical and personal circumstances of the intended parent.

Regulation of Fertility Clinics in California

California fertility regulation is best understood as a layered regulatory system rather than a single fertility-clinic law.

Different components of fertility care are regulated by different state and federal authorities.

Physician Licensing

Physicians practicing medicine in California must hold appropriate California licensure unless a statutory exception applies.

Allopathic physicians are regulated by the Medical Board of California, while osteopathic physicians are regulated through the state’s osteopathic medical licensing system.

Professional licensing rules apply to fertility physicians just as they do to physicians practicing in other medical specialties.

Clinical decisions, prescribing, procedures, medical documentation, informed consent, professional conduct, and standards of care all exist within the wider regulatory framework governing medical practice.

California Regulation of Reproductive Tissue Facilities

Reproductive medicine has an additional regulatory dimension because sperm, eggs, and embryos can fall within tissue-regulation frameworks.

The California Department of Public Health’s Laboratory Field Services Tissue Bank Section licenses and surveys several types of facilities, expressly including assisted reproductive technology facilities and sperm banks.

California identifies Health and Safety Code Sections 1635–1648 and 125300–125320 and California Code of Regulations Title 17 Sections 1235–1237 among the laws and regulations relevant to this framework.

The state’s licensing process for applicable ART tissue facilities can involve review of personnel, policies and procedures, quality assurance, tissue handling, patient consent forms, sexually transmitted disease screening policies, ownership information, and FDA registration where applicable.

This regulatory structure is important because fertility treatment involves not only medical appointments but also the collection, handling, storage, transfer, and preservation of highly sensitive human reproductive material.

Federal FDA Regulation of Donated Reproductive Tissue

The FDA provides another regulatory layer. Donated eggs and sperm are regulated under the federal framework for human cells, tissues, and cellular and tissue-based products.

Depending upon the activity performed and applicable exemptions, establishments may have registration, donor eligibility, screening, testing, recordkeeping, labeling, processing, storage, and good tissue practice obligations under 21 CFR Part 1271.

For reproductive donors, applicable infectious-disease testing can include testing specified under federal regulations and FDA guidance.

The FDA specifically identifies additional testing requirements for reproductive HCT/P donors for infections including Chlamydia trachomatis and Neisseria gonorrhoeae, subject to regulatory exceptions.

California Gamete Donor Information Rules

California also regulates information maintained concerning certain gamete donors.

California law requires licensed gamete banks, for covered donations, to collect and retain specified identifying and medical information from donors.

For gametes collected on or after January 1, 2020, a donor is given a choice concerning disclosure of identifying information to a person conceived using the donor’s gametes after that person reaches age 18.

Regardless of certain identity-disclosure choices, the law also provides access in qualifying situations to non-identifying medical information supplied by the donor.

These provisions apply subject to the statutory conditions and exceptions, including special treatment where the donor’s identity was already known to the recipient.

This issue is becoming increasingly important as reproductive medicine moves into an era in which genetic testing and consumer DNA databases have also changed traditional assumptions about donor anonymity.

Federal Reporting of IVF and ART Outcomes

Fertility centers performing assisted reproductive technology are also affected by federal reporting requirements.

Under the Fertility Clinic Success Rate and Certification Act of 1992, ART clinics are required to report data concerning their ART procedures.

The Centers for Disease Control and Prevention operates the National ART Surveillance System, or NASS, through which participating clinics report ART cycle information.

CDC states that clinics performing ART must annually submit data concerning the ART procedures they perform and that clinic-level standardized success rates are subsequently calculated and published. This provides patients with an important source of information.

However, fertility success rates must be interpreted carefully.

A clinic treating younger patients with relatively uncomplicated fertility conditions cannot automatically be compared with a center accepting older patients or patients with very difficult diagnoses.

The CDC itself cautions that clinic success rates may differ because clinics treat different patient populations and use different treatment methods.

A published clinic success rate therefore should never be interpreted as an individual patient’s personal probability of having a baby.

Fertility Insurance Coverage in California

California’s fertility-insurance landscape changed significantly in 2026.

Senate Bill (SB 729), signed in 2024 and implemented beginning January 1, 2026, requires applicable large-group health plans and insurance policies to provide coverage for the diagnosis and treatment of infertility and fertility services, including IVF.

Small-group plans subject to the law are required to offer fertility coverage rather than universally include it in every small-group contract.

The California Department of Managed Health Care notes that covered fertility services may include diagnostic and screening services, reproductive counseling, IVF, donor and surrogate services, and cryopreservation and storage of sperm, oocytes, and embryos, depending upon the applicable coverage requirements and plan.

Implementation of SB 729 was originally planned earlier but was delayed to January 1, 2026. California’s Department of Insurance also notes that implementation for CalPERS plans is delayed until July 1, 2027.

Coverage therefore remains highly dependent upon the type of insurance arrangement.

Patients should never assume that because fertility services are available in California, their particular insurance policy necessarily pays for all of them.

Coverage for Medically Necessary Fertility Preservation

Separate from the broader IVF coverage issue, California protects fertility preservation when covered medical treatment may cause iatrogenic infertility. Examples may include certain cancer treatments or other therapies capable of damaging reproductive capacity.

California regulators treat standard fertility-preservation services in qualifying circumstances as a covered basic healthcare service under applicable health plans.  This distinction is important.

A patient seeking egg freezing solely to delay parenthood may have a very different insurance situation from a patient who needs urgent fertility preservation before receiving chemotherapy.

Understanding Fertility Treatment Costs

Fertility treatment costs can vary substantially depending upon treatment complexity.

Patients may incur separate expenses for:

• physician consultations;
• diagnostic testing;
• fertility medications;
• ultrasound monitoring;
• blood testing;
• egg retrieval;
• anesthesia;
• embryology services;
• ICSI;
• genetic testing;
• embryo biopsy;
• cryopreservation;
• annual storage;
• frozen embryo transfer;
• donor sperm;
• donor eggs;
• donor-related expenses;
• gestational-carrier services;
• legal services;
• psychological evaluations;
• and specialty pharmacy services.

Patients considering treatment should request a written financial explanation that distinguishes between the medical treatment package and services billed separately by laboratories, pharmacies, genetic testing companies, storage facilities, attorneys, or other third parties.

Questions Patients Should Ask a California Fertility Clinic

Choosing a fertility center should involve more than asking, “What is your IVF success rate?”

Patients may also want to ask:

Who will manage my treatment?
Will the same physician remain involved throughout treatment, or will several physicians rotate through the patient’s care?

Where is the embryology laboratory?
Is it located at the same facility or elsewhere?

Who operates the laboratory?
Patients should understand whether laboratory services are internal or provided through another organization.

Which procedures are actually performed at this location?
A satellite fertility office may provide monitoring but not egg retrieval or embryo transfer.

How are eggs, sperm, and embryos identified and tracked?
Reproductive tissue identification and chain-of-custody procedures are critically important.

What happens during an emergency?
Patients undergoing ovarian stimulation or invasive procedures should know how after-hours concerns are handled.

What services are included in the quoted price?
Medication, genetic testing, anesthesia, cryopreservation, and annual storage may be separate expenses.

What happens to cryopreserved material if the practice closes or changes ownership?
Long-term tissue storage creates obligations that may continue for many years.

How should published success rates be interpreted for someone with my diagnosis and age?
An individualized prognosis is more useful than an isolated clinic percentage.

What are the policies concerning single embryo transfer?
Reducing avoidable multiple pregnancies can be an important component of modern fertility practice.

What counseling is available regarding donor conception or surrogacy?
Third-party reproduction can raise long-term psychological, medical, legal, and family considerations.

Fertility Treatment Is Both Medical and Personal

Few areas of healthcare combine advanced science with emotional decision-making as intensely as fertility medicine.

That is why our motto at FertilityClinics.us is: “Serving People with Science and Compassion”

Patients may move within a few months from basic diagnostic testing to decisions involving IVF, genetic testing, frozen embryos, donor eggs, donor sperm, gestational carriers, or long-term cryogenic storage.

Those decisions can affect not only the patient’s current medical care but also future children and future family relationships.

A strong fertility-care system therefore requires more than advanced technology.

It requires competent physicians, reliable laboratories, careful reproductive-tissue management, transparent financial practices, appropriate genetic counseling, meaningful informed consent, regulatory compliance, privacy protection, and respect for patients and families.

California’s Fertility-Care Landscape

California occupies a particularly important position in American reproductive medicine because several powerful factors come together in the state:

• advanced clinical fertility medicine;
• large and sophisticated embryology operations;
• fertility preservation;
• third-party reproduction;
• donor conception;
• gestational surrogacy;
• genetic testing;
• diverse family-building pathways;
• a detailed reproductive-tissue regulatory system;
• and an expanding fertility-insurance framework.

For patients, this creates substantial opportunity — but also complexity.

The best treatment decision is not necessarily the most technologically advanced treatment. It is the treatment that appropriately addresses the patient’s medical condition, reproductive goals, personal circumstances, risks, financial situation, and long-term family-building plans.

Patients should therefore approach fertility treatment as an informed journey rather than simply a medical transaction.

Medical Disclaimer

This article provides general educational information about fertility treatment and the regulatory environment in California. It is not medical, legal, insurance, or financial advice. Fertility treatment should be discussed with qualified healthcare professionals, and questions concerning surrogacy, parentage, donor arrangements, contracts, or insurance coverage should be reviewed with appropriately qualified professionals. Laws, regulations, insurance requirements, and medical standards can change over time.